Q4 2025 Afya Ltd Earnings Call Transcript
Key Points
- Afya Ltd (AFYA) achieved a 12% year-over-year revenue growth, reaching BRL3,697 million.
- Adjusted EBITDA grew over 50% year-over-year, reaching BRL1,680 million, with a margin increase of 130 basis points.
- The company reported a solid cash flow from operating activities, ending the period with BRL1,548 million, a 6% increase from the previous year.
- Afya Ltd (AFYA) maintained its leadership position in medical education with 3,755 approved medical seats and a 5% growth in undergrad medical students.
- The company announced a cash dividend of BRL307.4 million, reflecting a strong commitment to shareholder returns.
- B2B revenues in the medical practice solutions segment were soft over the last year, indicating potential challenges in market readiness or technology integration.
- Operational expenses increased only 1% year-over-year, which may indicate potential underinvestment in certain areas.
- The guidance for 2026 implies a lower EBITDA margin compared to 2025, with a midpoint of 43.5% versus 45.4% in 2025.
- There is uncertainty regarding the impact of new regulations and potential penalties on underperforming schools in the Ahmed exams.
- The company faces challenges in integrating products and services across its platform to enhance user experience and engagement.
Thank you for joining us for AFIS conference call. I'm here today with FS CEO Vigilli Gibong and our CFO Vi Andreblo.
During today's presentation, our executives will make forward-looking statements. Forward-looking statements can be related to future events, future financial or operating performance, known and unknown risks, uncertainties, and other factors that may cause fa's actual results to differ materially from those contemplated by these forward-looking statements.
Forward-looking statements in this presentation include, but are not limited to statements related to the business and financial performance, expectations and guidance for future periods or expectations regarding the company's strategic product initiatives, its related benefits.
These risks include those who are fully described in our findings of the Securities and Exchange Commission.
The forward-looking statements in this presentation are based on the information available to us as the date hereof. You should not rely on them as predictions of future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
